"Designing Growth Strategies is in our DNA"
Lymphoma is cancer that affects the part of our immune system which is called a human lymphatic system. Lymphoma starts when the lymphocytes divide in an uncontrolled manner. B lymphocytes are responsible for large lymphomas. Thus, diffuse large B-cell generates from B cell large and abnormal and are a different form of a normal B cell. Globally, diffuse large B cell lymphoma (DLBCL) is considered to be a common type of non-hodgkin lymphoma (NHL) which is the fastest growing and affects B lymphocytes. These B cell lymphocytes help in fighting against infections and help in the proper functioning of the lymphatic system. Furthermore, DLBCL develops in extranodal sites which include thyroid, skin, gastrointestinal tract, bone, breast, and others. It is most commonly observed in men than in women. Moreover, this type of lymphoma has enlarged B cell and cancer cells that are in extend out the pattern. Symptoms of lymphoma are weight loss, rise in temperature without any cause, heavy sweating, and others which are boosting the growth of the market. Various tests are conducted for diagnosis of lymphomas such as blood tests, removal of lymph node, biopsy, and others that are positively influencing the market growth during the forecast period.
Technological advancement coupled with advanced drug therapeutics is upscaling the growth of the market. Moreover, the increase in the prevalence of diffuse large B-cell lymphoma, an increase in cancer patients, and others are driving some of the factors that are driving the market in the near future. According to, the Cancer Research U.K it is estimated that annually 5,500 people are diagnosed with DLBCL, which makes about 40% of NHL cases in adults. Moreover, pharmaceutical industries have shifted their focus towards the development of advanced therapeutics for the treatment of DLBCL. In addition to this, an increase in pipeline candidates for the development of drugs for faster recovery of DLBCL is also triggering the market growth during the forecast period. For instance, the launch of biosimilars of rituximab drug type which has obtained a huge market as monotherapy as well as combination therapy.
Key Market Driver -
Increasing prevalence of B-cell lymphocyte patients across the globe
Key Market Restraint -
Introduction of generics
However, stringent regulations, delays in FDA approvals, patent expiry of drugs, and others are hindering the market growth during the forecast period. For instance, patent expiry of drugs like rituximab, which is widely used for the treatment of B-cell lymphoma, leading to the introduction of generics.
Some of the major companies that are present in the global diffuse large B-cell lymphoma therapeutics market are Novartis AG, Pfizer Inc, Merck & Co., Inc., GlaxoSmithKline plc, Abbott, F. Hoffmann-La Roche Ltd., and other players.
Targeted drug type named Rituximab is anti-CD20 monoclonal antibody has gained huge market share. Owing to increase in demand for treatment of DLCBL and launch of biosimilars in the market.
The global diffuse large B cell lymphoma (DLBCL) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market followed by Europe due to a number of factors such as the increasing prevalence of chronic diseases, increasing prevalence of DLBCL cases, increased healthcare awareness, developed healthcare infrastructure, and others. The market in the Asia Pacific is anticipated to emerge as highly growing due to an increase in the geriatric population, improved R& D in countries in economically emerging countries such as China and India, and others. Latin America and Middle East & Africa are expected to experience steady growth.
To gain extensive insights into the market, Request for Customization
By Drug Type
By Distribution Channels
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry